Management of Drug Reactions to First-Line Tuberculosis Medications

Initial Management of Drug Reactions

When a patient experiences a drug reaction to first-line tuberculosis medications, the recommended approach is to stop the suspected medications, monitor liver function until normalized, and then sequentially reintroduce drugs one by one with careful monitoring to identify the offending agent 1, 2
If liver enzyme levels rise to five times normal or bilirubin rises, immediately stop rifampicin, isoniazid, and pyrazinamide 1
For infectious TB or clinically unwell patients, continue treatment with non-hepatotoxic drugs such as streptomycin and ethambutol until liver function normalizes 1
For severe reactions like Stevens-Johnson syndrome, immediately stop all medications until symptoms resolve 3

Isoniazid should be reintroduced starting at 50 mg/day, increasing to 300 mg/day after 2-3 days if no reaction occurs, and continuing for 2-3 more days without reaction before adding the next drug 1, 2
Rifampicin should be reintroduced starting at 75 mg/day, increasing to 300 mg after 2-3 days, and further increasing to a weight-appropriate dose after 2-3 more days 1, 2
Pyrazinamide should be reintroduced starting at 250 mg/day, increasing to 1.0 g after 2-3 days, and further increasing to a weight-appropriate dose 1, 2

Monitor liver function tests if symptoms such as fever, malaise, vomiting, jaundice, or unexplained deterioration occur 1
Consider viral hepatitis testing to exclude coexistent viral causes 1

If isoniazid cannot be used, treatment will need to be continued for at least 12 months with rifampicin and ethambutol, supplemented with pyrazinamide for the initial two months 5, 6
If pyrazinamide cannot be used, treatment should be with rifampicin and isoniazid for nine months, supplemented with ethambutol for the initial two months 1, 7
If ethambutol cannot be used, the six-month regimen of rifampicin and isoniazid supplemented by two months' initial pyrazinamide is satisfactory 5

For multidrug-resistant TB, treatment should be conducted by physicians with substantial experience in managing complex resistant cases 7
In cases where drug options are extremely limited due to resistance patterns, desensitization protocols may be considered under the cover of two other anti-tuberculosis drugs 1
Combined drug preparations can be useful for compliance monitoring but should be used cautiously when reintroducing drugs after reactions 1

Daily monitoring of clinical condition and liver function during drug reintroduction is necessary 1
If a reaction recurs, the most recently added drug should be identified as the offending agent and permanently excluded 1
Alternative regimens should be developed under the supervision of a fully trained physician 1

The American Thoracic Society recommends rifampicin alone causes hepatitis in nearly 0% of cases, but in combination with isoniazid the rate is 2.7% 8, 9
Rifampicin is critical for short-course therapy and should generally be included despite hepatic disease, but with increased monitoring frequency 9

The American College of Chest Physicians notes that rifampicin enhances isoniazid hepatotoxicity through enzyme induction, so early hepatitis (<15 days) may actually be rifampicin-enhanced isoniazid toxicity rather than rifampicin alone 8, 9

In patients with tuberculosis who develop a maculopapular rash, postponing the stepwise re‑introduction of anti‑TB drugs increases the likelihood of treatment failure, disease relapse, and the emergence of drug‑resistant Mycobacterium tuberculosis strains【10, 11】.